Quang X Pham
CEO, CFO at Cadrenal Therapeutics, Inc. (CVKD); CEO, Chair at Cadrenal Therapeutics, Inc. (CVKD)
Purchase track record
Not enough history. Based on 0 purchases with a full 90 days of price history.
—
Avg. 90-day return—
vs. S&P 500—
Beat the market—
Paper profit on buys$0
Total bought / sold$0 / $499K
Reported trades
| Filed | Stock | Type | Shares | Price | Value | Since |
|---|---|---|---|---|---|---|
| Jul 1SEC | CVKDCadrenal Therapeutics, Inc. | Sell Plan | 7,40098,589 held (−7%) | $3.03 | $22K | -70.0% |
| Jun 26SEC | CVKDCadrenal Therapeutics, Inc. | Sell Plan | 2,127115,018 held (−2%) | $3.00 | $6K | -69.7% |
| Jun 26SEC | CVKDCadrenal Therapeutics, Inc. | Sell Plan | 9,029105,989 held (−8%) | $3.05 | $28K | -70.2% |
| Jun 24SEC | CVKDCadrenal Therapeutics, Inc. | Sell Plan | 9,167119,422 held (−7%) | $3.55 | $33K | -74.4% |
| Jun 24SEC | CVKDCadrenal Therapeutics, Inc. | Sell Plan | 2,277117,145 held (−2%) | $3.20 | $7K | -71.6% |
| Jun 18SEC | CVKDCadrenal Therapeutics, Inc. | Sell Plan | 3,613129,102 held (−3%) | $3.18 | $11K | -71.4% |
| Jun 18SEC | CVKDCadrenal Therapeutics, Inc. | Sell Plan | 513128,589 held (−0%) | $3.16 | $2K | -71.2% |
| Jun 15SEC | CVKDCadrenal Therapeutics, Inc. | Sell Plan | 1,462149,377 held (−1%) | $4.12 | $6K | -77.9% |
| Jun 15SEC | CVKDCadrenal Therapeutics, Inc. | Sell Plan | 12,996136,381 held (−9%) | $3.94 | $51K | -76.9% |
| Jun 15SEC | CVKDCadrenal Therapeutics, Inc. | Sell Plan | 3,666132,715 held (−3%) | $3.58 | $13K | -74.6% |
| Jun 10SEC | CVKDCadrenal Therapeutics, Inc. | Sell Plan | 5,893167,331 held (−3%) | $4.38 | $26K | -79.2% |
| Jun 10SEC | CVKDCadrenal Therapeutics, Inc. | Sell Plan | 12,992154,339 held (−8%) | $4.06 | $53K | -77.6% |
| Jun 10SEC | CVKDCadrenal Therapeutics, Inc. | Sell Plan | 3,500150,839 held (−2%) | $4.21 | $15K | -78.4% |
| Jun 5SEC | CVKDCadrenal Therapeutics, Inc. | Sell Plan | 2,323179,186 held (−1%) | $4.26 | $10K | -78.6% |
| Jun 5SEC | CVKDCadrenal Therapeutics, Inc. | Sell Plan | 3,898175,288 held (−2%) | $4.41 | $17K | -79.4% |
| Jun 5SEC | CVKDCadrenal Therapeutics, Inc. | Sell Plan | 2,064173,224 held (−1%) | $4.42 | $9K | -79.4% |
| Jun 2SEC | CVKDCadrenal Therapeutics, Inc. | Sell Plan | 303181,858 held (−0%) | $5.01 | $2K | -81.8% |
| Jun 2SEC | CVKDCadrenal Therapeutics, Inc. | Sell Plan | 349181,509 held (−0%) | $4.46 | $2K | -79.6% |
| May 29SEC | CVKDCadrenal Therapeutics, Inc. | Sell Plan | 6,476188,448 held (−3%) | $5.76 | $37K | -84.2% |
| May 29SEC | CVKDCadrenal Therapeutics, Inc. | Sell Plan | 3,298185,150 held (−2%) | $5.28 | $17K | -82.8% |
| May 29SEC | CVKDCadrenal Therapeutics, Inc. | Sell Plan | 2,989182,161 held (−2%) | $4.93 | $15K | -81.5% |
| May 26SEC | CVKDCadrenal Therapeutics, Inc. | Sell Plan | 1,165194,924 held (−1%) | $5.69 | $7K | -84.0% |
| Oct 28SEC | CVKDCadrenal Therapeutics, Inc. | Sell Plan | 1,129197,404 held (−1%) | $14.03 | $16K | -93.5% |
| Oct 28SEC | CVKDCadrenal Therapeutics, Inc. | Sell Plan | 1,315196,089 held (−1%) | $13.99 | $18K | -93.5% |
| Oct 14SEC | CVKDCadrenal Therapeutics, Inc. | Sell Plan | 1,800200,333 held (−1%) | $14.02 | $25K | -93.5% |
| Oct 14SEC | CVKDCadrenal Therapeutics, Inc. | Sell Plan | 1,800198,533 held (−1%) | $14.15 | $25K | -93.6% |
| Oct 3SEC | CVKDCadrenal Therapeutics, Inc. | Sell Plan | 500202,133 held (−0%) | $14.13 | $7K | -93.6% |
| Oct 1SEC | CVKDCadrenal Therapeutics, Inc. | Sell Plan | 419203,514 held (−0%) | $14.01 | $6K | -93.5% |
| Oct 1SEC | CVKDCadrenal Therapeutics, Inc. | Sell Plan | 881202,633 held (−0%) | $14.01 | $12K | -93.5% |
- Sell
CEO, Chair Quang X Pham sold $22K of CVKD at $3.03 — pre-scheduled 10b5-1 plan sale.
- Sell
CEO, CFO Quang X Pham sold $6K of CVKD at $3.00 — pre-scheduled 10b5-1 plan sale.
- Sell
CEO, CFO Quang X Pham sold $28K of CVKD at $3.05 — pre-scheduled 10b5-1 plan sale.
- Sell
CEO, CFO Quang X Pham sold $33K of CVKD at $3.55 — pre-scheduled 10b5-1 plan sale.
- Sell
CEO, CFO Quang X Pham sold $7K of CVKD at $3.20 — pre-scheduled 10b5-1 plan sale.
- Sell
CEO, CFO Quang X Pham sold $11K of CVKD at $3.18 — pre-scheduled 10b5-1 plan sale.